title: Intracellular expression in pig cells of anti-alpha1,3galactosyltransferase single-chain FV antibodies reduces Gal alpha1,3Gal expression and inhibits cytotoxicity mediated by anti-Gal xenoantibodies.
abstract: BACKGROUND
  The carbohydrate structure Gal alpha1,3Gal expressed on pig cells is the major antigen recognized by xenoreactive natural antibodies in the higher primates. In xenotransplantation, natural antibodies binding to that structure initiate hyperacute rejection, and the anti-Gal alpha1,3Gal antibodies that are elicited probably take part in later phases of vascularized graft rejection. This epitope also appears to be involved in innate cellular responses. Inactivation of alpha1,3 galactosyltransferase in transgenic pigs would certainly lead to the success of xenotransplantation, but gene knockout in pigs is not feasible yet.
  
  
  METHODS
  As a novel strategy to inhibit alpha1,3 galactosylation, we generated recombinant single-chain Fv (ScFv) antibodies directed against pig alpha1,3-galactosyltransferase and evaluated the effect of their intracellular expression on enzyme activity and Gal alpha1,3Gal expression.
  
  
  RESULTS
  After in vitro transfection in pig cells, the scFv antibody anti-pig alpha1,3-galactosyltransferase reduced the amount or function of enzyme by up to 70% as evidenced by immunofluorescence and measurement of cell-associated activity. Consequently, Gal alpha1,3Gal on cell membranes was reduced to the same extent. This led to a profound (more than 90%) reduction in the cytotoxicity involving anti-Gal antibodies and complement.
  
  
  CONCLUSIONS
  Although not sufficient to knock out the overall human anti-pig natural xenoreactivity, intracellular expression of the scFv antibody anti-alpha1,3-galactosyltransferase in pig cells significantly decreases the amount of Gal alpha1,3Gal and could be important to protect cells from elicited antibodies as well as from innate effectors.
authors.affiliation: INSERM U437, Institut National de la Santé et de la Recherche Médicale, CHU-Hotel Dieu, Nantes, France. bvanhove@nantes.inserm.fr
authors.forename: B
authors.initials: B
authors.lastname: Vanhove
authors.forename: B
authors.initials: B
authors.lastname: Charreau
authors.forename: A
authors.initials: A
authors.lastname: Cassard
authors.forename: C
authors.initials: C
authors.lastname: Pourcel
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
mesh_terms: D000818:Animals; D000906:Antibodies; D000910:Antibodies, Heterophile / Q000494:pharmacology; D002460:Cell Line; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D000939:Epitopes; D005455:Fluorescent Antibody Technique; D005690:Galactose / Q000276:immunology*; D005700:Galactosyltransferases / Q000276:immunology*; D006801:Humans; D013347:Subcellular Fractions / Q000737:chemistry; D013552:Swine
chemical_list: D000906:Antibodies; D000910:Antibodies, Heterophile; D000939:Epitopes; D005700:Galactosyltransferases; C037959:beta-D-galactosyl-N-acetylglucosaminylglycopeptide alpha-1,3-galactosyltransferase; D005690:Galactose